 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || TT-00920 / TransThera Biosci
Trial completion, Enrollment change: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects (clinicaltrials.gov) - Nov 18, 2023
P1, N=20, Completed, Sponsor: TransThera Sciences (Nanjing), Inc.
Recruiting --> Completed | N=30 --> 20
- || TT-00920 / TransThera Biosci
Trial completion: A Phase 1 Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - Feb 27, 2023
P1, N=30, Completed, Sponsor: TransThera Sciences (Nanjing), Inc.
Recruiting --> Completed | N=30 --> 20 Recruiting --> Completed
- || TT-00920 / TransThera Biosci
Trial completion, Trial completion date: Phase I, First-In-Human Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - Feb 27, 2023
P1, N=42, Completed, Sponsor: TransThera Sciences (Nanjing), Inc.
Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> Mar 2022
- || TT-00920 / TransThera Biosci
New P1 trial: A Phase 1 Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - May 1, 2022
P1, N=30, Recruiting, Sponsor: TransThera Sciences (Nanjing), Inc.
- || TT-00920 / TransThera Biosci
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Phase I, First-In-Human Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - Nov 3, 2021
P1, N=42, Active, not recruiting, Sponsor: TransThera Sciences (Nanjing), Inc.
Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> Mar 2022 Recruiting --> Active, not recruiting | N=72 --> 42 | Trial completion date: Feb 2021 --> Nov 2021 | Trial primary completion date: Jan 2021 --> Jun 2021
- || TT-00920 / TransThera Biosci
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects (clinicaltrials.gov) - Sep 14, 2021
P1, N=30, Recruiting, Sponsor: TransThera Sciences (Nanjing), Inc.
- valsartan / Generic mfg.
[VIRTUAL] TT-00920, a Clinical Stage Novel Phosphodiesterase 9 Inhibitor, Protects Against Heart Failure in a Rat Model of Myocardial Infarction (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_3063;
P1
The superior efficacy of TT-00920/Valsartan combination suggests that TT-00920 and renin-angiotensin-aldosterone system inhibitors may have additive therapeutic effects in heart failure. TT-00920 is currently being evaluated in Phase 1 clinical study for safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers (NCT04364789).
- ||| TT-00920 / TransThera Biosci
New P1 trial: Phase I, First-In-Human Study of TT-00920 in Healthy Subjects (clinicaltrials.gov) - Apr 27, 2020
P1, N=72, Recruiting, Sponsor: TransThera Biosciences Co., Ltd